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Abstract 
Background: SPINK1 (serine protease inhibitor, kazal-type, 1), which encodes human 
pancreatic secretory trypsin inhibitor, is one of the most extensively studied genes underlying 
chronic pancreatitis. Recently, based upon data from qualitative reverse transcription-PCR 
(RT-PCR) analyses of transfected HEK293T cells, we concluded that 24 studied SPINK1 
intronic variants were not of pathological significance, the sole exceptions being two 
canonical splice site variants (i.e., c.87+1G>A and c.194+2T>C). Herein, we employed the 
splicing prediction tools included within the Alamut software suite to prioritize the ‘non-
pathological’ SPINK1 intronic variants for further quantitative RT-PCR analysis.  
Results: Although our results demonstrated the utility of in silico prediction in classifying and 
prioritizing intronic variants, we made two observations worth noting. First, we established 
that most of the prediction tools employed ignored the general rule that GC is a weaker donor 
splice site than the canonical GT site. This finding is potentially important because for a given 
disease gene, a GC variant donor splice site may be associated with a milder clinical 
manifestation. Second, the non-pathological c.194+13T>G variant was consistently predicted 
by different programs to generate a new and viable donor splice site, the prediction scores 
being comparable to those for the physiological c.194+2T donor splice site and even higher 
than those for the physiological c.87+1G donor splice site. We do however provide 
convincing in vitro evidence that the predicted donor splice site was not entirely spurious. 
Conclusions: Our findings, taken together, serve to emphasize the importance of functional 
analysis in helping to establish or refute the pathogenicity of specific intronic variants. 
Keywords: Aberrant mRNA transcripts, Chronic pancreatitis, In silico, Intronic variants, 
Non-canonical splice sites, Quantitative RT-PCR analysis, SPINK1, Splicing phenotype 
prediction 
Background 
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SPINK1 (serine protease inhibitor, kazal-type, 1; OMIM #167790), which encodes pancreatic 
secretory trypsin inhibitor, is one of the most extensively studied genes underlying chronic 
pancreatitis [1]. Of the some 90 different nucleotide sequence variants listed in the Chronic 
Pancreatitis Genetic Risk Factors Database (http://www.pancreasgenetics.org/index.php; 
accessed 2 Jan 2017), 31 (34%) are intronic, a difficult category of sequence variant to 
ascertain in terms of their potential pathological relevance. Recently, using a ‘maxigene’ 
expression assay for which the full-length SPINK1 genomic sequence (approximately 7 kb 
stretching from the translational initiation codon to the stop codon of the four-exon gene) was 
cloned into the pcDNA3.1/V5-His-TOPO vector, we analyzed the functional consequences of 
24 SPINK1 intronic variants for the mRNA splicing phenotype in transfected HEK293T cells 
by means of reverse transcription-PCR (RT-PCR) analysis. Based upon the observed splicing 
patterns, we concluded that none of the studied variants, apart from the two canonical splice 
site variants (i.e., c.87+1G>A and c.194+2T>C), were of pathological significance [2, 3].  
However, upon reflection, we felt that whereas our conclusions regarding the two 
canonical splice site variants were solid, those relating to the other 22 intronic variants could 
have been too hasty. For example, some of these 22 intronic variants might have caused 
aberrant splicing albeit to a limited extent. However, such aberrantly spliced transcripts may 
have been rapidly degraded by the cellular mRNA quality control system as compared with 
the correctly spliced transcripts, resulting in a quantitative decrease in terms of the correctly 
spliced transcripts. To explore this possibility, we employed the commonly used in silico 
splicing prediction programs to prioritize these SPINK1 intronic variants for further 
quantitative RT-PCR analysis.  
 
Materials and methods  
In silico splicing prediction 
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All 24 of the SPINK1 intronic variants previously analyzed by the maxigene assay [2, 3] were 
re-examined in the context of in silico splicing prediction by means of Alamut® Visual 
version 2.7.1 (Interactive Biosoftware, Rouen, France) that included five prediction 
algorithms viz. SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and Human 
Splicing Finder. We focused exclusively on the potential impact of the SPINK1 intronic 
variants in terms of the disruption of known splice sites or the creation of new potential splice 
sites. We firstly used data derived from the two canonical splice site variants (i.e., c.87+1G>A 
and c.194+2T>C) as a first means to assess the performance of each of the five prediction 
programs. We then used the selected programs to prioritize variants for quantitative RT-PCR 
analysis. 
 
Quantitative RT-PCR analysis of four prioritized variants in the context of a maxigene 
assay 
Four variants (i.e., c.87+363A>G, c.194+13T>G, c.194+1504A>G and c.195-323C>T) were 
prioritized for quantitative RT-PCR analysis. The wild-type and variant expression vectors 
harboring the corresponding full-length genomic SPINK1 genes have been previously 
described [2, 3]. HEK293T cell culture, transfection, reverse transcription and real-time 
quantitative RT-PCR analyses were performed as described [4], except that the primer pair 
used for amplifying the full-length target gene transcripts was changed to 5’-
GGAGACCCAAGCTGGCTAGT-3’ (forward) and 5’-AGACCGAGGAGAGGGTTAGG-3’ 
(reverse); the forward and reverse primers are located within the pcDNA3.1 5'- and 3'-
untranslated regions, respectively (i.e., the primer pair Q1 as described in [5]). 
 
Further analyses of the c.194+13T>G variant in the context of a maxigene assay 
Analysis of nonsense-mediated mRNA decay (NMD) 
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This analysis was performed as described in [4], with the CEL-HYB1 and CEL-HYB2a 
expression vectors being replaced by the aforementioned full-length SPINK1 wild-type and 
c.194+13T>G variant gene expression vectors, respectively.  
 
Identification of the in silico predicted aberrant transcript 
The c.194+13T>G variant was consistently predicted by the selected four programs to create a 
putative splice donor site (see Results and discussion). An allele-specific forward primer, 5’-
ATGTTTTGAAAATCGGTGAGTAC-3’, was used together with the reverse primer of the 
aforementioned primer pair Q1 [5] to amplify this predicted aberrant transcript. The PCR 
program comprised an initial denaturation at 95°C for 15 min, followed by 35 cycles of 
denaturation at 94°C for 45 s, annealing at 58°C for 45 s, and extension at 72°C for 1 min.  
 
Estimation of the frequency of the aberrant transcripts relative to the wild-type transcripts 
Using the aforementioned primer pair Q1, we performed RT-PCR to amplify the full-length 
transcripts prepared from the c.194+13T>G variant maxigene-transfected HEK293T cells 
treated with cycloheximide. After addition of 3′-A overhangs, the purified products were 
cloned into the pcDNA3.1/V5-His-TOPO vector (Invitrogen, Carlsbad, CA). Transformation 
was performed using XL10-Gold Ultracompetent Cells (Stratagene, La Jolla, CA) and 
transformed cells were spread onto LB agar plates with 50 mg/mL ampicillin and incubated at 
37°C overnight [4]. Bacterial colonies were picked to be added into a 25 μl PCR mixture, 
which contained 12.5 μl HotStarTaq Master Mix (QIAGEN), 0.4 μM each primer (i.e., primer 
pair C1 in [5]; the forward and reverse primer sequences are located within the beginning and 
end regions of the SPINK1 coding sequence, respectively). The PCR had an initial 
denaturation step at 95°C for 15 min, followed by 30 cycles of denaturation at 94°C for 45 s, 
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annealing at 58°C for 45 s, and extension at 72 °C for 45 s. The samples showing the expected 
band on the gel were cleaned and sequenced using the forward primer. 
 
Further analyses of the c.194+13T>G variant in the context of a minigene assay 
Minigene construction and mutagenesis 
A 567-bp fragment spanning the exon 3 of SPINK1 as well as 230 bp flanking intronic 
sequences on both sides (Additional file 1) was amplified using primers 5′-
CGGGCCCCCCCTCGAGTTTCAGAAGGGCCATAGGAC-3′ (forward) and 5′-
TAGAACTAGTGGATCCCCAAGCTATCGACTATTTTGCTG-3′ (reverse). PCR was 
performed in a 25 μl reaction mixture containing 0.5 U KAPA HiFi HotStart DNA 
Polymerase, 5 μl 5× KAPA HiFi Buffer, 0.75 μl dNTP Mix, 20 ng expression vector 
containing the full-length wild-type SPINK1 genomic sequence [5], and 0.3 μM each primer. 
The PCR program comprised an initial denaturation at 95°C for 5 min, followed by 30 cycles 
of denaturation at 98°C for 20 s, annealing at 66°C for 15 s, extension at 72°C for 15 s, and a 
final extension at 72 °C for 5 min. The PCR products were cloned into the Exontrap vector 
pET01 (MoBiTec) that was linearized by restriction enzymes BamHI and XhoI, using the In-
Fusion® HD Cloning kit (Clontech) in accordance with the manufacturer’s instructions. The 
resulting expression vector was termed the wild-type SPINK1 exon 3 minigene.  
The c.194+13T>G variant was introduced into the wild-type SPINK1 exon 3 minigene as 
previously described for introducing the same variant into the wild-type SPINK1 maxigene 
vector [2], except that the extension time was reduced from 13 to 5 min. The successful 
introduction of the variant was confirmed by DNA sequencing using primers 5′-
GTAGCTGCCAGGAAGGAGTG-3′ (forward) and 5′-GGCCTCCAAAACCTACACAT-3′ 
(reverse). 
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Qualitative and quantitative RT-PCR analyses 
HEK293T cell culture, transfection, and reverse transcription were performed as previously 
described [2]. Qualitative RT-PCR was performed in a 25 μl mixture containing 12.5 μl 
HotStarTaq Master Mix (QIAGEN), 0.4 μM each primer (5′-
GAGGGATCCGCTTCCTGGCCC-3′ (forward) and 5′-CTCCCGGGCCACCTCCAGTGCC-
3′ (reverse)) and 1 μl cDNA. The program had an initial denaturation at 95°C for 15 min, 
followed by 30 cycles of denaturation at 94°C for 45 s, annealing at 58°C for 45 s, and 
extension at 72°C for 2 min. PCR products were cleaned by ExoSAP-IT (Affymetrix) and 
sequenced using a BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). 
Quantitative RT-PCR analysis was done as previously described [4], except that the 
primers used for target gene amplification were changed to those used for the aforementioned 
qualitative RT-PCR analysis. 
 
Results and discussion 
The increasingly routine use of whole genome sequencing has led to the discovery of an 
increasing number of rare variants, particularly intronic variants, owing to the relatively large 
size of intronic sequences as compared to the exonic sequences of protein-coding genes. It is, 
in practice, generally unrealistic to functionally analyze the large number of intronic variants 
detected in protein-coding genes. In silico prediction is therefore commonly used both to 
classify and prioritize intronic variants for further functional analysis [6, 7]. Herein, we 
adopted this approach to prioritize SPINK1 intronic variants, which had been previously 
classified as ‘non-pathological’ in accordance with data obtained from qualitative RT-PCR 
analyses of transfected HEK293T cells [2, 3], for further quantitative analysis. To this end, we 
predicted the impact on mRNA splicing of all 24 previously functionally analyzed SPINK1 
intronic variants by means of the widely used Alamut software suite, focusing on their 
8 
 
potential disruption or creation of splice sites in accordance with previous studies [7, 8]. The 
corresponding score changes for each variant, predicted by each of the five prediction 
programs included within Alamut, are summarized in Additional file 2.  
 
Using data from two canonical splice site variants as a first means to assess the relative 
performance of the five splicing prediction programs 
There are currently no consensus guidelines as to which prediction tools should be used or 
how the results of predictions should be interpreted [9]. Importantly, of the 24 SPINK1 
intronic variants studied here, c.87+1G>A and c.194+2T>C affected canonical splice donor 
splice sites and were the only tested variants that had been previously shown to result in 
aberrant splicing using a maxigene assay [2, 3]. We therefore used data from these two 
variants as a means to assess the relative performance of the five splicing prediction programs 
included within the Alamut software suite. 
 
GeneSplicer was excluded from consideration owing to its poor performance in relation to the 
two corresponding wild-type alleles 
We first assessed the relative performance of the five splicing prediction programs by 
evaluating their prediction scores with respect to the corresponding wild-type alleles of the 
two canonical splice site variants. SpliceSiteFinder-like, MaxEntScan, NNSPLICE and 
Human Splicing Finder all yielded scores that were ≥79.8% of their respective maxima. 
However, GeneSplicer only yielded a score of <27% of its maximum (Additional file 3), and 
was therefore excluded from further consideration.  
 
A particular observation with respect to the c.194+2T>C variant 
9 
 
We then correlated the prediction scores from the four selected programs and the known 
splicing phenotypes in relation to the two canonical splice site variant alleles. In the context of 
the c.87+1G>A variant allele, SpliceSiteFinder-like, MaxEntScan, NNSPLICE and Human 
Splicing Finder all predicted a score of zero (Table 1). This prediction was consistent with the 
complete exon 2 skipping that was observed in the maxigene assay [2].  
A particular observation was made in the context of the c.194+2T>C variant. This variant 
was shown to lead to two distinct transcripts, one wild-type, the other lacking exon 3, the 
aberrant transcript being expressed at a much higher level than the wild-type transcript in our 
maxigene assay [2]. These results not only concur with those obtained from the analysis of 
mRNA derived from stomach tissue (in which SPINK1 is also abundantly expressed) from a 
c.194+2T>C homozygote [10] but are also consistent with the general rule that GC is a less 
frequently used and weaker splice donor site as compared to the canonical GT site [11, 12]. 
However, only SpliceSiteFinder-like predicted a consistent reduced score (from 82.6 to 72.3) 
whilst MaxEntScan, NNSPLICE and Human Splicing Finder all predicted a score of zero 
(Table 1). 
Taken together, in the context of the two canonical splice site variants, a good correlation 
was noted between the predictions of SpliceSiteFinder-like, MaxEntScan, NNSPLICE and 
Human Splicing Finder and the in vitro maxigene-obtained functional results, although only 
SpliceSiteFinder-like yielded a perfect correlation in both cases. 
 
                                 INSERT TABLE 1 ARUOND HERE 
 
In silico prioritization of the 22 ‘non-pathological’ variants for further quantitative 
analysis 
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We classified the 22 empirically tested ‘non-pathological’ SPINK1 intronic variants into three 
categories in accordance with the predictions by SpliceSiteFinder-like, MaxEntScan, 
NNSPLICE and Human Splicing Finder (Additional file 2). 
Category 1 comprised 13 variants, none of which were predicted to affect splicing by any 
of the four programs. These variants were excluded from further functional analysis. 
Category 2 comprised three variants that were only predicted (and only by Human 
Splicing Finder) to disrupt a putative splice acceptor or donor site (i.e., c.88-352A>G, 
c.194+90A>T and c.194+184T>A). These predictions were clearly inappropriate because (i) 
the SPINK1 gene is not known to have alternative transcripts and (ii) we did not observe any 
alternative transcripts from the wild-type SPINK1 gene in the maxigene assay. They were 
therefore also excluded from further functional analysis. 
Category 3 comprised 6 variants, each being predicted by at least one program to create a 
new donor or acceptor splice site. Of these, c.194+13T>G was predicted by all four programs 
to create a potential donor splice site and both c.194+1504A>G and c.195-323C>T were 
predicted by three of the four programs to create a potential donor splice site. These three 
variants were selected for further functional analysis (Table 1).  
The remaining three category 3 variants were all predicted by one and the same program 
(i.e., Human Splicing Finder) to create a new donor or acceptor splice site (i.e., 
c.87+363A>G, c.195-1570C>A and c.195-1399G>A). Of these, we selected that which had 
the highest predicted score (i.e., 83.3 of the maximum score of 100; c.87+363A>G), for 
further analysis (Table 1).  
 
All four prioritized variants were not found to significantly reduce mRNA expression by 
quantitative RT-PCR analysis 
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We performed quantitative RT-PCR analysis of the HEK293T cells co-transfected with each 
of the expression vectors harboring the respective full-length variant SPINK1 genes and the 
reference PGL3-GP2 plasmid [4, 5]. We did not however observe statistically significant 
differences in mRNA expression level between any of the four variants and the wild-type 
(Fig. 1).  
 
Further analyses of the c.194+13T>G variant 
Of the four variants subjected to quantitative RT-PCR analysis, c.194+13T>G was the only 
one that was consistently predicted by the SpliceSiteFinder-like, MaxEntScan, NNSPLICE 
and Human Splicing Finder programs to create a potential donor splice site, with each 
program predicting a relatively high score (Table 1). Indeed, the predicted scores for this 
variant were even higher than, or at least equal to, the corresponding ones for the 
physiological c.87+1G donor splice site (Table 1). Moreover, the predicted scores for this 
variant were comparable to those for the physiological c.194+2T donor splice site (Table 1), 
the two sites being separated by only 10 bp. 
The use of the predicted splice donor site would lead to the generation of an aberrant 
transcript containing a premature stop codon (Fig. 2a). Such a transcript might be subject to 
significant degradation by NMD [14], leading to a reduced mRNA expression level. In this 
regard, the aforementioned quantitative RT-PCR analyses hinted at a possible reduced level of 
expression of the correctly spliced transcripts from the c.194+13T>G variant maxigene (Fig. 
1). To clarify this issue, we performed further quantitative RT-PCR analysis of the 
c.194+13T>G variant maxigene-transfected HEK293T cells with or without treatment with 
cycloheximide (a known NMD inhibitor [15]) as previously described [4] but no statistically 
significant changes were observed (Additional file 4). Additionally, we analyzed the impact 
on splicing of the c.194+13T>G variant in the context of a minigene assay. We found only a 
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single band whose size was similar to that of the wild-type (Additional file 5a) and whose 
identity to the wild-type sequence was confirmed by sequencing the RT-PCR product. We 
further performed quantitative RT-PCR analysis of the HEK293T cells co-transfected with the 
c.194+13T>G variant-containing minigene expression vector and the PGL3-GP2 plasmid. We 
did not observe statistically significant differences in mRNA expression level between the 
c.194+13T>G variant and the wild-type (Additional file 5b). 
We then speculated that such an aberrant transcript might exist but at such an extremely 
low level as compared to the correctly spliced transcript that it would be beyond the detection 
limit of quantitative RT-PCR analysis. We therefore designed an allele-specific forward 
primer (rightward blue arrow in Fig. 2a) in an attempt to detect this aberrant transcript if it 
were to exist. Use of this forward primer and a reverse primer located within the pcDNA3.1 
3'-untranslated region succeeded in detecting a specific RT-PCR product from the 
c.194+13T>G variant maxigene-transfected HEK293T cells (both with and without 
cycloheximide treatment) but not in the wild-type SPINK1 maxigene-transfected HEK293T 
cells (Fig. 2b). Sequencing of this specific RT-PCR product confirmed the use of predicted 
novel splice donor site (Fig. 2c). 
To obtain an approximate estimate of the expression level of the aberrant transcript 
relative to the correctly spliced transcript, we then performed colony PCRs followed by 
sequencing of the full-length transcripts amplified from the c.194+13T>G variant maxigene-
transfected HEK293T cells treated with cycloheximide. Sequencing of 100 PCR products of 
expected size revealed only wild-type transcript. [Note that the wild-type and aberrant 
transcripts are indistinguishable by gel analysis owing to their length difference of only 12 bp; 
see Fig. 2a.] This suggested that the c.194+13T>G variant resulted in less than 1% of 
aberrantly spliced transcripts relative to the amount of wild-type transcript. 
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Conclusions 
In silico prioritization and subsequent quantitative RT-PCR analyses of selected SPINK1 
intronic variants for further functional characterization in a maxigene assay supported our 
previous classification of 24 SPINK1 intronic variants as having pathological relevance (or 
not) in chronic pancreatitis [2, 3]. As in many studies, our results demonstrated the utility of 
in silico prediction in classifying and prioritizing intronic variants. However, we made two 
observations worth noting during this study. First, we found that most of the prediction 
programs included within the commonly used Alamut software suite ignore the general rule 
that GC is a weaker donor splice site as compared with the canonical GT donor splice site. 
This finding serves to remind us of a key point in medical genetics: in a given disease gene, a 
C introduced into the second position of a canonical GT donor splice site may have a milder 
clinical manifestation than a G or A. Second, the non-pathological c.194+13T>G variant was 
consistently predicted by the selected four programs to generate a potential donor splice site, 
the prediction scores being even higher than the physiological c.87+1G splice site. However, 
by means of allele-specific PCR, we provided convincing in vitro evidence that the predicted 
donor splice site was not entirely spurious (Fig. 2). These findings, taken together, serve to 
emphasize the importance of functional analysis in helping to establish or refute the 
pathogenicity of certain intronic variants, an issue of increasing importance in the new age of 
precision medicine [16, 17]. This notwithstanding, it should be pointed out that in the context 
of the c.194+13T>G variant, it would be desirable to investigate its effect in the 
corresponding carrier’s pancreatic tissue. However, obtaining such a tissue sample would be 
extremely difficult particularly given that the c.194+13T>G variant has so far been reported 
only once [18]. 
 
Additional files  
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Additional file 1: Figure S1. The SPINK1 sequence cloned into the Exontrap vector pET01.  
Additional file 2: Table S1. In vitro observed and in silico predicted mRNA splicing 
phenotypes associated with the 24 SPINK1 intronic variants under study. 
Additional file 3: Figure S2. Alamut-predicted impact of the SPINK1 c.87+1G>1, 
c.194+2T>C and c.194+13T>G variants on the disruption or creation of splice sites. 
Additional file 4: Figure S3. Relative mRNA expression levels of the SPINK1 c.194+13T>G 
variant-containing maxigene in transfected HEK293T cells in the presence (gray) and absence 
(black) of cycloheximide as determined by quantitative RT-PCR analysis. Results are given as 
the mean  SD from three independent transfection experiments. 
Additional file 5: Figure S4. Further analyses of the SPINK1 c.194+13T>G variant in a 
minigene assay. a RT-PCR analyses of HEK293T cells transfected with minigene expression 
vectors carrying the wild-type and c.194+13T>G variant. Empty vector, the Exontrap vector 
pET01. b Relative mRNA expression level of the c.194+13T>G variant compared to that of 
the wild-type as determined by quantitative RT-PCR analysis of HEK293T cells transfected 
with the corresponding minigene expression constructs. Results are given as the means  SD 
from three independent transfection experiments. 
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Figure legends 
 
Fig. 1 Relative mRNA expression levels associated with four variant SPINK1 gene constructs 
compared to that of the wild-type, as determined by the quantitative RT-PCR analysis of 
HEK293T cells transfected with various maxigene expression constructs. Results are given as 
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the mean  SD from three independent transfection experiments. No statistically significant 
difference in mRNA expression level was noted between any of the variants and the wild-
type. 
 
 
Fig. 2 Confirmation of the Alamut-predicted creation of a new splice donor site by the 
SPINK1 c.194+13T>G variant. a Schemas for the splicing of intron 3 with respect to the wild-
type and variant alleles of c.194+13T>G. The splice donor (GT) and splice acceptor (AG) 
signals potentiating the normal and aberrant splicing of intron 3 are highlighted in bold and 
underlined. The rightward pointing blue arrow indicates the forward allele-specific primer 
designed to amplify the predicted aberrant transcript (as shown in b). The 12 bp intronic 
sequence inappropriately included within the predicted aberrant transcript is indicated by a 
red box. The amino acid sequences of the wild-type and predicted mutant proteins are also 
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shown. b PCR identification of the aberrant transcripts expressed from the HEK293T cells 
transfected with the c.194+13T>G variant-containing maxigene expression construct. The 
primers used for amplification were the forward allele-specific primer as illustrated in (a) and 
a reverse primer located within the 3’ untranslated region of the expression vector. No PCR 
products were identified in cells transfected with the wild-type maxigene expression vector. 
Plus and minus symbols refer to cells treated with and without cycloheximide, respectively. c 
Sequence of the c.194+13T>G/+ PCR products as illustrated in (b). The 12 bp intronic 
sequence included within the aberrant transcript is indicated by a red box. 
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